Does research-grade semaglutide produce the same weight-loss results as Ozempic
Part of this was reflective of the fact that work on other intestinal peptides had proven disappointing
Semaglutide, initially developed as a treatment for type 2 diabetes, is part of a drug class known as GLP-1 receptor agonists
The SHAPE study, analyzing real-world prescribing data, found: At 3 months: tirzepatide users lost 5.9% of body weight versus 3.6% for semaglutide At 6 months: 10.1% versus 5.8% At 12 months: 15.3% versus 8.3% These are averages from actual patients, not trial participants
Ahead, I spoke with two experts to unpack GLP-1 costs, including how pricing works, how insurance factors in and why monthly costs can vary so widely
Rather than rushing to maximum doses, your provider will carefully evaluate your weight loss progress, side effects, hunger levels, and nutritional status each month before making dosage adjustments